New drug aims to stop Alzheimer's before it starts in gene carriers
Prevention
Not yet recruiting
This study tests whether the drug HT-4253 can lower Alzheimer's risk in people aged 50-75 who carry the APOE4 gene and have high levels of amyloid in their blood. The 112 participants will receive either the drug or a placebo for 48 weeks. The main goal is to see if the drug can …
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC